

The Medical Letter[®]

on Drugs and Therapeutics

Volume 65

Published online June 7, 2023

Online
Article

IN THIS ISSUE

In Brief: Brexucabtagene autoleucl (*Tecartus*) for Acute Lymphoblastic Leukemia

Important Copyright Message

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying, or any distribution of this material without permission to a nonsubscriber is prohibited.

Sharing a password with a nonsubscriber or otherwise making the contents of this site available to third parties is prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)
or call customer service at: 800-211-2769

The Medical Letter®

on Drugs and Therapeutics

Volume 65

Published online June 7, 2023

Online
Article

IN THIS ISSUE

In Brief: Brexucabtagene autoleucel (*Tecartus*) for Acute Lymphoblastic Leukemia

IN BRIEF

Brexucabtagene autoleucel (*Tecartus*) for Acute Lymphoblastic Leukemia

Brexucabtagene autoleucel (*Tecartus* – Kite) has been approved by the FDA for treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). It was previously approved for treatment of relapsed or refractory mantle cell lymphoma. *Tecartus* is an individualized cellular product prepared from the patient's own T cells, which are genetically modified to express chimeric antigen receptors (CAR) and then infused back into the patient. The CAR T-cell immunotherapy tisagenlecleucel (*Kymriah*) was approved in 2017 for treatment of relapsed or refractory B-cell precursor ALL in patients ≤ 25 years old.¹

Pronunciation Key

Brexucabtagene autoleucel: brex" ue kab' ta jeen
aw" toe loo' sel
Tecartus: tek ahr thus

THE PROCEDURE – Brexucabtagene autoleucel is prepared from autologous T cells obtained by leukapheresis. The T cells are sent to a commercial laboratory, which genetically modifies them via retroviral transduction to insert an anti-CD19 CAR transgene. *Tecartus* is supplied in a patient-specific, single-dose infusion bag. Before infusion of the genetically modified T cells, patients usually receive lymphodepleting chemotherapy (cyclophosphamide and fludarabine).

CLINICAL STUDIES – FDA approval of the CD19-directed CAR T-cell therapy for the new indication was based on the results of a single arm trial in 55 adults with relapsed or refractory B-cell precursor ALL. Patients were treated with a conditioning regimen of cyclophosphamide and fludarabine and then

with anti-CD19 CAR T cells. After a median follow-up of 26.8 months, the overall complete remission rate was 71%; the median duration of remission was 14.6 months and median overall survival was 25.4 months.²

ADVERSE EFFECTS – The *Tecartus* label includes a boxed warning about the risk of cytokine release syndrome (CRS), a common complication of CAR T-cell immunotherapy that can cause hypotension, pulmonary edema, coagulopathy, multiorgan failure and death, and about the risk of neurologic toxicity (CAR T-cell encephalopathic syndrome). In the pivotal clinical trial, CRS occurred in 92% and neurologic toxicity occurred in 87% of patients. CRS has been successfully treated with the IL-6 receptor antagonist tocilizumab (*Actemra*), with or without corticosteroids.

PREGNANCY AND LACTATION – Brexucabtagene autoleucel has not been studied in pregnant or lactating females and is not recommended for use during pregnancy or while breastfeeding. There are no data on the presence of brexucabtagene autoleucel in human breast milk or its effect on the breastfed infant or milk production.

DOSAGE, ADMINISTRATION, AND COST – For treatment of ALL, cyclophosphamide should be administered once daily for 3 days before and fludarabine one day before the single infusion of 1×10^6 CAR-positive viable T cells/kg (target dose; max 1×10^8 cells) in a ~68-mL suspension. Patients should receive acetaminophen and an anti-histamine about 30-60 minutes before infusion of *Tecartus*. They should be monitored at the treatment facility for 2 weeks after the infusion and stay near the treatment facility for at least 4 weeks. The cost for one dose of *Tecartus* is \$424,000 for the drug alone.³ ■

1. Tisagenlecleucel (Kymriah) for ALL. *Med Lett Drugs Ther* 2017; 59:177.
2. BD Shah et al. Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study. *J Hematol Oncol* 2022; 15:170.
3. Approximate WAC. WAC = wholesaler acquisition cost or manufacturer's published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. June 5, 2023. Reprinted with permission by First Databank, Inc. All rights reserved. ©2023. www.fdbhealth.com/policies/drug-pricing-policy.

PRESIDENT: Mark Abramowicz, M.D.; **VICE PRESIDENT, EDITOR IN CHIEF:** Jean-Marie Pflomm, Pharm.D.; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Michael P. Viscusi, Pharm.D. **CONSULTING EDITORS:** Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

CONTRIBUTING EDITORS: Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Neal H. Steigbigel, M.D., New York University School of Medicine; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS: Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

FULFILLMENT AND SYSTEMS MANAGER: Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli
EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS: Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

Subscription Services

Address:

The Medical Letter, Inc.
145 Huguenot St. Ste. 312
New Rochelle, NY 10801-7537
www.medicalletter.org

Customer Service:

Call: 800-211-2769 or 914-235-0500
Fax: 914-632-1733
E-mail: custserv@medicalletter.org

Permissions:

To reproduce any portion of this issue,
please e-mail your request to:
permissions@medicalletter.org

Subscriptions (US):

1 year - \$159; 2 years - \$298;
3 years - \$398. \$65 per year
for students, interns, residents,
and fellows in the US and Canada.
Reprints - \$45 per issue or article

Site License Inquiries:

E-mail: SubQuote@medicalletter.org
Call: 800-211-2769
Special rates available for bulk
subscriptions.

Get Connected:    

Copyright 2023. ISSN 1523-2859

The
Medical
Letter